ADDEX STARTS PHASE 2 CLINICAL STUDY OF ADX71149 FOR EPILEPSY First patients enrolled into multi-center U.S. study Geneva, Switzerland, June 7, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting – Exploratory Analysis of the INVICTUS Phase 3 Study Showed QINLOCK Dose Escalation After Disease Progression Provided...
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma – Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND)...
Recent Comments